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Summary
Background. — In patients with acute myocardial infarction (MI), cardiogenic shock (CS) remains
associated with a high mortality (close to 50%) despite optimal therapeutic strategy. For those
patients who are unlikely to survive, mechanical circulatory support (MCS) might be an additional
life saving strategy. 
Objective. — To evaluate the efficacy of circulatory assistance in myocardial infarction
complicated by cardiogenic shock. 
Methods. — We retrospectively studied the characteristics and clinical outcome of 10 patients
hospitalized with acute MI and CS who required MCS. Mean age was 52±8 years; location of MI
was anterior in 80% of cases. Immediate coronary angiography was performed in all cases
5.8±7.0 hours from the onset of symptoms. Intra-aortic balloon pumping was used in 70% of
patients and 30% received thrombolysis. Angioplasty with stent implantation was performed in
8 patients. 
Results. — In all patients MCS was placed within a mean of 57±92 hours after admission for
hemodynamic instability (systolic aortic pressure: 85±13 mmHg; mean: 64±10 mmHg).
Extracorporeal membrane oxygenation (ECMO) was implanted in 8 patients followed by
Thoratec™ in one. The other 2 patients received a Thoratec™ and a Heartmate II™ system
respectively. Survival rate was 40% (4 patients): 3 patients underwent heart transplantation at
a mean of 93±97 days and one patient is alive with definitive implantable Heartmate™. The
other six patients died in hospital.
Conclusion. — Mechanical circulatory support appeared life saving in 4 out of 10 patients with
acute MI and cardiogenic shock refractory to optimal treatment. In this situation, circulatory
assistance deserves discussion and the choice of optimal device should be further evaluated.
© 2008 Published by Elsevier Masson SAS.
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Résumé
Justification. — Malgré une stratégie thérapeutique optimale, la mortalité des patients en choc
cardiogénique (CC) à la phase aiguë de l'infarctus du myocarde (IDM) reste élevée proche de
50%. Pour ces patients au pronostic vital engagé, l’assistance circulatoire mécanique (ACM) est
une alternative thérapeutique. 
Objectifs. — Evaluer l’efficacité d’une assistance circulatoire dans le choc cardiogénique
compliquant un infarctus du myocarde. 
Méthodes. — Nous avons étudié rétrospectivement les caractéristiques cliniques et l’évolution
de 10 patients hospitalisés pour IDM compliqué de CC, ayant nécessité une ACM. L'âge moyen
était de 52±8 ans, l’IDM était antérieur dans 8 cas. Une coronarographie a été réalisée en
urgence dans tous les cas, 5,8±7 heures après le début des symptômes. Un ballon de
contrepulsion intra-aortique a été utilisé dans 70% des cas et 30% des patients ont été traités
par thrombolyse. Une angioplastie a été réalisée chez 8 patients. 
Résultats. — Une ACM a été mise en place 57±92 heures après l'admission pour instabilité
hémodynamique (pression aortique systolique : 85±13 mmHg ; moyenne : 64±10 mmHg). Une
ECMO a été implantée chez 8 patients, suivie d’un Thoratec dans un cas. Les 2 autres patients
ont reçu un Thoratec™ et un Heartmate II™. Le taux de survie était de 40% : 3 patients ont été
transplantés dans un délai de 93+/-97 jours et un patient a été assisté par le dispositif
Heartmate II™. Les autres patients sont décédés pendant la période hospitalière. 
Conclusion. — L'ACM a permis la survie de 4 patients sur 10 à la phase aigue d’un IDM compliqué
de CC réfractaire au traitement conventionnel. Dans cette situation, l’assistance circulatoire
mérite d’être discutée.
© 2008 Published by Elsevier Masson SAS.
Introduction
While the widespread use of initial reperfusion intervention
has lead to a significant reduction in overall mortality from
myocardial infarction (MI), cardiogenic shock (CS) remains a
life-threatening complication (mortality rate of approxima-
tely 50%) and is still the primary cause of death in patients
hospitalized for MI (1). In fact, over the past 25 years the
incidence of cardiogenic shock has shown no sign of reduc-
tion, remaining a major complication in 8 to 10% of all trea-
ted MI (2). Inotropes, vasopressors and intra-aortic balloon
pump (IABP) provide an increase in cardiac output of
approximately 0.5l/min. When a larger increase is neces-
sary, mechanical circulatory support (MCS) may offer an
interesting alternative therapeutic approach. It should enable
sufficient hemodynamic stability to be maintained while
diminishing the workload on the heart, hence aiding its
recovery. The use of emergency mechanical support has
been frequently discussed in MI complicated by cardiogenic
shock (3). Its use was first described in 1986 (4). Since then
numerous reports of its usage have been published (5). In
this study, we report our results from employing mechani-
cal circulatory support in MI complicated by refractory car-
diogenic shock.
Methods
This is a retrospective, single-centre, descriptive study of
10 consecutive patients hospitalized between January 2000
and December 2006 (the first patient was admitted in
January 2000 and the other 9 after January 2002). The
patients were admitted to the Charles Nicolle Hospital in
Rouen with MI complicated by cardiogenic shock, necessita-
ting the implantation of a device providing mechanical
circulatory assistance. 
Myocardial infarction was defined as an acute coronary
syndrome associated with chest pain, ST-segment elevation
with Q-wave or a left bundle branch block on ECG. The dia-
gnosis of cardiogenic shock was made if there was prolon-
ged hypotension (systolic arterial pressure < 90mmHg for at
least 30 minutes or the need to use inotropic or vasopres-
sive pharmacological agents to maintain systolic arterial
pressure ≥ 90 mmHg), the presence of clinical signs of peri-
pheral hypoperfusion and a heart rate of ≥ 60 beats per
minute. Right heart cardiac catheterization was not carried
out systematically. Immediate angiographic success was
defined as stent placement with < 30% residual stenosis and
a normal arterial flow (TIMI [Thrombosis In Myocardial
Infarction] flow grade 3).
The mechanical circulatory assistance device used most
frequently in our study was the Extracorporeal Membrane
Oxygenation (ECMO) system (Medos® Berlin, and Jostra®
Hirrlingen, Germany). This extracorporeal circulation sys-
tem can pump the same volume as the heart and therefore
sustain the patient stably. The ECMO is implanted percuta-
neously or by surgical insertion into the femoral vessels.
The cannula implanted into the femoral vein is guided
upwards to the right atrium to drain venous blood. A centri-
fugal pump pushes the blood across the oxygenator and it is
reinjected into the aorta via a cannula implanted in a peri-
pheral artery. The Thoratec™ PVAD (Paracorporeal Ventri-
cular Assist Device) system was used in our first patient and
an IVAD (Intracorporeal Ventricular Assist Device) system
in another case. This device offering biventricular mecha-
nical circulatory assistance is driven by an external pneu-
matic energy source connected to a either fixed or mobile
console.
The artificial ventricles were so positioned as to bypass the
patient’s heart, which was left in place. The HeartMate II™
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system is a left ventricular assist device where the power-
pack is connected midway between the point of the left
ventricle and the aorta. The inflow cannula is connected to
the apex of the left ventricle and the outflow cannula is
sutured terminolaterally to the ascending aorta. Electrical
energy is provided via a console or batteries, which permit
several hours of autonomy. Circulatory assistance devices
such as the Thoratec™ and HeartMate II™ (Thoratec Corpo-
ration, Pleasanton, CA) require surgical implantation and
sternotomy. In our centre the procedure is always carried
out with the patient on extracorporeal circulatory bypass. 
The follow-up of patients was made possible by the use of
the Charles Nicolle Hospital’s computerized medical record
management system (CDP2). All values were expressed as
mean ± standard deviation. 
Results
Between 2002 and 2006, 679 patients with acute myocardial
infarction (AMI) underwent coronary angiography in our
center. Amongst these, 39 (4.4%) presented with cardioge-
nic shock. In 10 of these patients it was necessary to
implant a mechanical circulatory assist device. The mean
age of these patients was 52±8 years (41 to 64 years). The
female to male ratio was 1 to 9 men. The predominant risk
factor was smoking (70%) followed by hypercholesterolemia
(40%) and hypertension (30%). Additionally, 20% of patients
had a family history of MI. 
The infarction in 8 patients was located in the anterior
wall and in the other two in the inferior wall. The initial
medical treatment of the MI was provided by the ambulance
service (SAMU) in 80% of cases within an average delay of
3.9± 8h from symtom onset. Four of the patients were
resuscitated following cardiac arrest and 5 others were
intubated and ventilated. Thrombolysis was performed pre-
admission in 30% of patients within 57±17 min. Seven
patients were admitted directly to the catheterization
laboratory, while two patients needed immediate medical
resuscitation and the last patient was admitted into the
intensive care unit. On admission, mean systolic aortic
pressure was 85±13 mmHg; mean arterial pressure
64±10 mmHg. Eight patients were in cardiogenic shock on
admission and the other two developed shock within
12 hours. All patients received pharmacological support
with inotropes and/or vasopressors. No sign of mechanical
complication was evident on ultrasound examination. The
mean ejection fraction was 23±8% and the peak troponin Ic
was 896 ± 865 µg/l (normal < 1µg/l). The treatment moda-
lities for all patients are summarized in table 1.
Coronary angiography was carried out in all cases within
a mean delay of 5.8±7 hours from symptom onset. Four
patients had triple vessel disease, 3 had double and the
three remaining single vessel disease. The culprit arteries
were: the left main stem in one case, the left anterior des-
cending in 5 cases, the circumflex in 2 cases and the right
coronary in 2 cases. Angioplasty with stenting was success-
ful in 80% of the patients (1.7 stents per patient). In the
remaining 20% of cases no endovascular intervention was
possible. Percutaneous revascularization was not complete
in 3 patients. An intra-aortic balloon pump was placed in
seven patients.
Mechanical circulatory assist device was implanted
within a mean of 57±92 hours following the diagnosis of car-
diogenic shock. Five patients had MCS on the day of their
admission, three others within 48 h of admission and two
after a delay of more than a week. Extracorporeal mem-
brane oxygenation was used in 8 cases while the two other
patients benefited from more sophisticated ventricular
assist devices: a Thoratec™ and a HeartMate II™.
Six patients died within a mean of 2.6±1.3 days after
ECMO assistance was initiated: three from multi-organ
failure, two from irreversible neurological damage and one
from fatal hemodynamic imbalance. Of the four surviving
patients, one is still dependant on the implanted
Heartmate II™ after 16 months and three have undergone
heart transplant. Amongst these, two have benefited from
the strategy of "bridge to transplantation" with one of them
having a transplant 8 days after ECMO and the other after
200 days of assisted circulation with the Thoratec™ PVAD.
The strategy "bridge to bridge" was used for one patient
who was assisted by ECMO for 14 days before it was repla-
ced by the Thoratec™ IVAD, with transplantation 72 days
later. The mean time before a mechanical circulatory
device was implanted was less than 24 h in the group of
patients who died and 5.2±5 days in those who survived
(Table 2).
Discussion
The first report of mechanical ventricular assistance dates
from 1966 (6). Since then surgical techniques,devices and
methods of resuscitation have continuously improved. A
recent meta-analysis (5), which grouped more than
500 patients with MCS for cardiogenic shock found a hospi-
tal survival rate in the order of 50%, comparable with that
found in our study. 
Tableau 1 Patient treatment characteristics (n =10)
Admitted from:
Ambulance service 8
Secondary transfer 1
Emergency department 1
Treatment onset
Pain / ambulance service (hour) 3.9± 8
Pain / Coronary angiography (hour) 5.8 ± 7
Hemodynamic state
Initial cardiac arrest 4
MI location: — Anterior 8
— Inferior 2
Initial state of shock 8
Intubation / ventilation 5
Inotropes : — adrenaline / dobutamine 8
— noradrenaline / dopamine 2
IABP 7
 SAP (mmHg) 85 ± 13
 Mean arterial pressure (mmHg) 64 ± 10
Transthoracic echocardiography :
 — mechanical complication 0
— ejection fraction (%) 23 ± 8
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The utility of MCS in acute heart failure (7), hypothermia
(8) and cases of acute drug intoxication is unquestioned due
to its high success rate. The situation is very different in
myocardial infarction. The studies published on the use of
mechanical circulatory support in MI are difficult to inter-
pret, due to their limited number (fewer than 30) and small
sample size (1 to 26 patients). Other limitations of these
studies include: the absence of randomization between
conventional treatment approaches and MCS, the absence
of comparable clinical criteria leading to the use of an
assist device and the wide variation in the type of MCS devi-
ces used. 
Despite the absence of randomized trials or guidelines
(9), it is clear now that patients remaining in cardiogenic
shock despite conventional treatment (IABP, inotropes and
revascularization) have no hope of survival. Under these
circumstances the option of mechanical circulatory support
should be considered particularly in those patients suitable
for heart transplant. 
The criteria leading to the use of an assist device post-MI
remain to be defined. In our study only clinical data (arte-
rial pressure, signs of peripheral shock, age and co-morbidi-
ties) were considered. Other studies have used hemodyna-
mic parameters (10) and one even a prognostic score (11).
The timing of the implantation of the device would seem
to be of the outmost importance. It must be carried out
before multi-system failure becomes irreversible, even if
evaluation of neurological function is often difficult to
assess. As shown by Jaski et al. (12) in a group of 10 patients
assisted after cardiac arrest, implantation of ECMO was
achieved more quickly in those patients who survived
(17±10 min) than those who did not (54±11 min). We found
the opposite in the present study, all our patients who died
had been implanted within 24 hours of their admission whe-
reas the mean time to implantation in the survivors was
48 h. This finding is perhaps explained by the seriousness of
the clinical condition in the non-surviving patients who
already had a very poor prognosis at the time of implant of
the MCS device. In fact four patients had presented with
cardiac arrest and three of these died from the effects of
irreversible neurological damage. The three other deaths in
our group were early (two from systemic organ failure and
1 from hemodynamic instability). The earlier the interven-
tion is performed the better the results from mechanical
circulatory assistance. However, this rapidity also means
that sometimes patients will be implanted in whom the
effects of cardiogenic shock are already irreversible. Under
these circumstances, the method “bridge to bridge” beco-
mes of interest. The results of Aiba et al. (13) seem to con-
firm this observation. In his series, 64 patients with post-MI
cardiogenic shock received MCS, either by intra-aortic bal-
loon pump or extracorporeal membrane oxygenation. If the
patients were in severe cardiogenic shock there was 100%
mortality regardless of the method of mechanical assis-
tance, whereas if they were in a state of moderate cardio-
genic shock survival rates were 38% with ECMO assistance
and 5% with IABP. 
Implantation of the MCS device needs to be achieved as
quickly as possible in the case of cardiac arrest, but it
would seem that for cases of refractory cardiogenic shock
the most important prognostic parameter is the severity of
the initial shock. 
Considering the MCS devices used, Chen et al. (14) and
Parkes et al. (10) used the more sophisticated type of
device, Heartmate™, with a very high level of transplanta-
tion (70%) in the patients studied. Even if this type of sys-
tem gives good results, it is difficult to recommend its
front-line use for several reasons. Firstly implantation
requires the absence of multisystem or irreversible neurolo-
gical failure, something which is difficult to judge in an
emergency situation.Additionally the implantation is a
lengthy and expensive procedure, costing approximately
85,000 €. The ECMO System is cheaper (2,000 to 6,000 €),
easy and rapid to position. Above all it enables temporary
stabilization of hemodynamic parameters long enough to
both evaluate the neurological state and decide on the sub-
sequent treatment options (15). Therefore two strategies
can be considered: 1) immediate emergency transplanta-
tion (ECMO acting as a “bridge to transplantation”), or 2) a
strategy of replacement with a more performant device so
that the patient can be assisted for as long as possible
before transplantation, known as “bridge to bridge”. 
In our patient series only two patients were implanted
with the more complex type of mechanical assist device. In
one case this was because of occlusive peripheral arterial
disease and in the other due to controlled hemodynamics
with neurological competence. 
Our current practise in refractory cardiogenic shock is
therefore fairly standard. It consists of the use of ECMO in
those patients who are potential transplant candidates and
secondarily, as a function of their general and neurological
state, the patient either undergoes cardiac transplant or
continues to be supported by a ventricular assist device. 
We would like to draw attention to the recent introduction
of a range of miniaturized centrifugal pumps (Impella® Reco-
ver LP 2.5 and 5, Aachen, Germany) which are mounted on a
catheter and can be inserted via the femoral route to the left
ventricle (16). An output of between 2.5 and 5 l/min can be
generated. These devices show superiority compared with
intra-aortic balloon pumps in terms of increased cardiac out-
put in a randomized trial ISAR-SHOCK (17). Nevertheless, the
better hemodynamic results achieved with the Impella® were
not able to alter prognosis in the small test group. Another
device implanted percutaneously, the Tandem Heart® (Car-
diac Assist Technologies, Inc) has been evaluated and simi-
Tableau 2 Mechanical assistance and clinical outcome
(n =10)
Mean time until implantation from onset of 
shock (hours) 
57 ± 92
Type of device :
ECMO 8
HeartMate 1
Thoratec 2 *
Outcome
Survivors : 4
— Transplantation 3
— Definitive Assistance 1
Deaths : 6
 Cause : — Systemic organ failure 3
— Neurological 2
— Hemodynamic failure 1
 Mean time to death after MCS (days) 2.6 ±1.3
* 1 patient with ECMO followed by Thoratec
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larly compared with IABP in a randomized trial. Despite
improved hemodynamic parameters outcome at 30 days was
comparable between the two groups in a series of 42 patients
(18).
Our study is limited by the small number of patients,
their relative heterogeneity (4 patients presented with car-
diac arrest associated with the state of shock) and also from
being a single-center study. A randomized, multicenter trial
is ongoing in France comparing extracorporeal membrane
oxygenation alone with ECMO combined with intra-aortic
balloon pump in the treatment of MI complicated by cardio-
genic shock. 
Conclusion
We have shown that in acute myocardial infarction compli-
cated by refractory cardiogenic shock, mechanical circula-
tory assistance combined with optimal conventional treat-
ment enabled the survival of 4 out of 10 patients. In such
clinically severe conditions, the use of circulatory assis-
tance should be proposed systematically and discussed on a
case by case basis taking into consideration the delays in
treatment, the severity of the shock and above all, the ulti-
mate possibility of transplant for the patient.
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